Suggested remit: To appraise the clinical and cost effectiveness of alectinib within its marketing authorisation as adjuvant treatment of ALK-positive non-small-cell lung cancer (NSCLC).
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6368

Provisional Schedule

Committee meeting: 1 03 October 2024
Expected publication 11 December 2024

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors Roche (alectinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups ALK Positive UK
  Asthma and Lung UK
  Black Health Agency for Equality
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Oncogene-Driven Lung Cancer Patient Alliance
  Roy Castle Lung Cancer Foundation
  Ruth Strauss Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Lung Cancer Coalition
Professional groups Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  British Geriatrics Society
  British Institute of Radiology
  British Oncology Pharmacy Association
  British Psychosocial Oncology Society
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Lung Cancer and Mesothelioma Clinical Expert Group
  Lung Cancer Nursing UK
  National Heart and Lung Institute
  Primary Care Respiratory Society UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Aspire Pharma (pemetrexed)
  Bristol Myers Squibb (paclitaxel)
  Dr Reddy’s Laboratories (pemetrexed)
  Eli Lilly (pemetrexed)
  Genus Pharmaceuticals (pemetrexed)
  Medac (oxaliplatin)
  Merck Sharp & Dohme UK (pembrolizumab)
  Pfizer (cisplatin, carboplatin, docetaxel, oxaliplatin, paclitaxel, pemetrexed)
  Ranbaxy UK [a Sun Pharmaceuticals company] (oxaliplatin)
  Sandoz (cisplatin, pemetrexed)
  Seacross Pharmaceuticals (paclitaxel, oxaliplatin, docetaxel)
  Teva UK (paclitaxel)
  Zentiva (pemetrexed)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups British Association of Lung Research
  Cochrane Airways Group
  Cochrane Lung Cancer Group
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Institute for Health & Care Research


Key events during the development of the guidance:

Date Update
05 March 2024 Invitation to participate
22 January 2024 - 05 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6368
22 January 2024 In progress. Scoping commencing
24 October 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual